Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
Michael R. McClung(Bone Health and Osteoporosis Foundation), Robert R. Recker(Creighton University), José Zanchetta(Universidad del Salvador), David E. Burgio(Procter & Gamble (United States)), Paul D. Miller(University of North Carolina at Chapel Hill), Jacques P. Brown(Centre hospitalier de l'Université Laval), Michael A. Bolognese, L. K. McCullough, J. Sarley, C. L. Benhamou(Inserm), Ana Balske(Providence Center)
Cited by 46
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait
|The American Journal of Human Genetics|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k